Nine-Weeks Treatment With 683699 In Subjects With Moderately-To-Severely Active Crohn's Disease
Status:
Completed
Trial end date:
2006-07-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the effectiveness and safety of the investigational drug 683699 in
treating subjects with moderately to severely active CD (Crohn's Disease).